Literature DB >> 17675541

Dose-response relationship of insulin glulisine in subjects with type 1 diabetes.

Reinhard H A Becker1, Annke D Frick, Leszek Nosek, Lutz Heinemann, Klaus Rave.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17675541     DOI： 10.2337/dc06-2114

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  12 in total

Review 1.  Continuous glucose monitoring-guided insulin dosing in pump-treated patients with type 1 diabetes: a clinical guide.

Authors:  Allen B King
Journal:  J Diabetes Sci Technol       Date:  2012-01-01

Review 2.  Increasing local blood flow by warming the application site: beneficial effects on postprandial glycemic excursions.

Authors:  Guido Freckmann; Stefan Pleus; Cornelia Haug; Gabriel Bitton; Ron Nagar
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

3.  Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes.

Authors:  Areti Philotheou; Silva Arslanian; László Blatniczky; Valentina Peterkova; Elisabeth Souhami; Thomas Danne
Journal:  Diabetes Technol Ther       Date:  2011-02-03       Impact factor: 6.118

4.  Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control.

Authors:  Itamar Raz; Gabriel Bitton; Dmitry Feldman; Tal Alon; Andreas Pfutzner; William V Tamborlane
Journal:  J Diabetes Sci Technol       Date:  2015-04-16

Review 5.  Insulin glulisine: a review of its use in the management of diabetes mellitus.

Authors:  Karly P Garnock-Jones; Greg L Plosker
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.

Authors:  Reinhard H A Becker; Annke D Frick
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Confusion Regarding Duration of Insulin Action: A Potential Source for Major Insulin Dose Errors by Bolus Calculators.

Authors:  John Walsh; Ruth Roberts; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2014-01-01

8.  Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes.

Authors:  G B Bolli; S Luzio; S Marzotti; F Porcellati; C Sert-Langeron; B Charbonnel; Y Zair; D R Owens
Journal:  Diabetes Obes Metab       Date:  2011-03       Impact factor: 6.577

9.  Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.

Authors:  Tim Heise; Kirstine Stender-Petersen; Ulrike Hövelmann; Jacob Bonde Jacobsen; Leszek Nosek; Eric Zijlstra; Hanne Haahr
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

10.  A Population Dose-Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects.

Authors:  D Rüppel; R Dahmen; A Boss; R Jäger; M Grant; R Baughman; T Klabunde
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.